Mark Agulnik

10.1k total citations · 1 hit paper
165 papers, 4.2k citations indexed

About

Mark Agulnik is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Pathology and Forensic Medicine. According to data from OpenAlex, Mark Agulnik has authored 165 papers receiving a total of 4.2k indexed citations (citations by other indexed papers that have themselves been cited), including 96 papers in Pulmonary and Respiratory Medicine, 94 papers in Oncology and 34 papers in Pathology and Forensic Medicine. Recurrent topics in Mark Agulnik's work include Sarcoma Diagnosis and Treatment (70 papers), Vascular Tumors and Angiosarcomas (30 papers) and Head and Neck Cancer Studies (24 papers). Mark Agulnik is often cited by papers focused on Sarcoma Diagnosis and Treatment (70 papers), Vascular Tumors and Angiosarcomas (30 papers) and Head and Neck Cancer Studies (24 papers). Mark Agulnik collaborates with scholars based in United States, United Kingdom and Canada. Mark Agulnik's co-authors include Lillian L. Siu, Joel B. Epstein, Scott H. Okuno, Gregory R. Pond, Ari J. Rosenberg, Margaret von Mehren, Jessica Lee Yarber, Bruce Brockstein, Brian A. Van Tine and Robert S. Benjamin and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Mark Agulnik

158 papers receiving 4.2k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial

2016 436 citations William D. Tap, Robin L. Jones et al. profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author						Papers	Cites
Mark Agulnik	2.6k	2.1k	847	782	620	165	4.2k
Antonio López–Pousa	1.7k 0.6×	1.9k 0.9×	541 0.6×	804 1.0×	448 0.7×	161	3.4k
Scott H. Okuno	2.5k 1.0×	3.6k 1.7×	959 1.1×	1.2k 1.5×	1.0k 1.6×	178	5.8k
Salvatore Lo Vullo	2.3k 0.9×	2.4k 1.1×	785 0.9×	1.4k 1.8×	652 1.1×	79	4.9k
Frédéric Peyrade	3.3k 1.3×	2.5k 1.2×	897 1.1×	1.5k 1.9×	408 0.7×	138	5.7k
Marco Merlano	2.2k 0.9×	1.4k 0.7×	1.3k 1.6×	848 1.1×	281 0.5×	188	4.6k
Juergen Dunst	1.2k 0.4×	1.5k 0.7×	410 0.5×	1.5k 1.9×	236 0.4×	118	4.0k
Jürgen Dunst	1.8k 0.7×	3.0k 1.4×	770 0.9×	2.4k 3.1×	948 1.5×	234	6.9k
A. Altendorf-Hofmann	3.7k 1.4×	1.6k 0.8×	544 0.6×	2.2k 2.8×	110 0.2×	124	5.8k
Anne Kirkpatrick	1.9k 0.8×	2.5k 1.2×	468 0.6×	1.6k 2.0×	155 0.3×	16	4.4k
Hiroyasu Yokomise	1.1k 0.4×	2.2k 1.0×	1.2k 1.4×	1.2k 1.6×	371 0.6×	220	4.5k

Countries citing papers authored by Mark Agulnik

Since Specialization

Citations

This map shows the geographic impact of Mark Agulnik's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Agulnik with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Agulnik more than expected).

Fields of papers citing papers by Mark Agulnik

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark Agulnik. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Agulnik. The network helps show where Mark Agulnik may publish in the future.

Co-authorship network of co-authors of Mark Agulnik

This figure shows the co-authorship network connecting the top 25 collaborators of Mark Agulnik. A scholar is included among the top collaborators of Mark Agulnik based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark Agulnik. Mark Agulnik is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Wilky, Breelyn A., Gary K. Schwartz, Michael S. Gordon, et al.. (2025). Botensilimab (Fc-enhanced anti–cytotoxic lymphocyte-association protein-4 antibody) Plus Balstilimab (anti–PD-1 antibody) in Patients With Relapsed/Refractory Metastatic Sarcomas. Journal of Clinical Oncology. 43(11). 1358–1368. 9 indexed citations

Hwang, Caleb, Mark Agulnik, & Brian Schulte. (2024). Prices and Trends in FDA-Approved Medications for Sarcomas. Cancers. 16(8). 1545–1545. 1 indexed citations

Wagner, Andrew J., Jonathan C. Trent, Steven Attia, et al.. (2024). Peak part 1 summary: A phase 3, randomized, open-label multicenter clinical study of bezuclastinib (CGT9486) and sunitinib combination versus sunitinib in patients with gastrointestinal stromal tumors (GIST).. Journal of Clinical Oncology. 42(16_suppl). 11533–11533. 1 indexed citations

Dumbrava, Ecaterina E., Fábio M. Iwamoto, Mark Agulnik, et al.. (2024). Abstract CT066: Phase 1 study of MDM2 antagonist ASTX295 in patients with solid tumors with wild-type TP53. Cancer Research. 84(7_Supplement). CT066–CT066. 1 indexed citations

Schöffski, Patrick, Robin L. Jones, Mark Agulnik, et al.. (2024). Current unmet needs in locally advanced (unresectable) or metastatic dedifferentiated liposarcoma, the relevance of progression-free survival as clinical endpoint, and expectations for future clinical trial design: an international Delphi consensus report. ESMO Open. 9(7). 103487–103487. 1 indexed citations

Heinrich, Michael C., Neeta Somaiah, Jonathan C. Trent, et al.. (2024). Peak study: A phase 3, randomized, open-label multicenter clinical study of bezuclastinib (CGT9486) and sunitinib in combination versus sunitinib in patients with gastrointestinal stromal tumors (GIST).. Journal of Clinical Oncology. 42(3_suppl). TPS766–TPS766. 1 indexed citations

Konda, Bhavana, Eric J. Sherman, Erminia Massarelli, et al.. (2024). Cabozantinib Plus Ipilimumab/Nivolumab in Patients With Previously Treated Advanced Differentiated Thyroid Cancer. The Journal of Clinical Endocrinology & Metabolism. 110(3). 830–837. 4 indexed citations

Chawla, Sant P., Vivek Subbiah, Nam Q. Bui, et al.. (2023). 1939P phase I clinical results of SQ3370, a doxorubicin-based click chemistry therapeutic in advanced solid tumor patients. Annals of Oncology. 34. S1041–S1041. 1 indexed citations

Yoon, Janet, et al.. (2023). Bioinformatic Analysis of Recurrent Genomic Alterations and Corresponding Pathway Alterations in Ewing Sarcoma. Journal of Personalized Medicine. 13(10). 1499–1499. 1 indexed citations

10.

Dominguez, Dana A., Sagus Sampath, Mark Agulnik, et al.. (2023). Surgical Management of Retroperitoneal Sarcoma. Current Oncology. 30(5). 4618–4631. 6 indexed citations

11.

Wei, Christina, Evita Sadimin, Mark Agulnik, et al.. (2023). SMARCA4/BRG1-deficient Uterine Neoplasm With Hybrid Adenosarcoma and Carcinoma Features: Expanding the Molecular-morphologic Spectrum of SMARCA4-driven Gynecologic Malignancies. International Journal of Gynecological Pathology. 43(4). 354–361. 1 indexed citations

12.

Ravi, Vinod, Scott M. Schuetze, Sujana Movva, et al.. (2022). OER‐073: A multicenter phase 2 study evaluating the role of pazopanib in angiosarcoma. Cancer. 128(19). 3516–3522. 12 indexed citations

13.

Riedel, Richard F. & Mark Agulnik. (2022). Evolving strategies for management of desmoid tumor. Cancer. 128(16). 3027–3040. 28 indexed citations

14.

Attia, Steven, Vanessa Bolejack, Kristen N. Ganjoo, et al.. (2022). A phase II trial of regorafenib in patients with advanced Ewing sarcoma and related tumors of soft tissue and bone: SARC024 trial results. Cancer Medicine. 12(2). 1532–1539. 30 indexed citations

15.

Davis, Lara E., Vanessa Bolejack, Christopher W. Ryan, et al.. (2019). Randomized Double-Blind Phase II Study of Regorafenib in Patients With Metastatic Osteosarcoma. Journal of Clinical Oncology. 37(16). 1424–1431. 174 indexed citations

16.

Rosenberg, Ari J. & Mark Agulnik. (2018). Epithelioid Hemangioendothelioma: Update on Diagnosis and Treatment. Current Treatment Options in Oncology. 19(4). 19–19. 99 indexed citations

17.

Chae, Young Kwang, Sachin Gopalkrishna Pai, Peng Sun, et al.. (2016). Fibroblast Growth Factor Receptor (FGFR) as a Therapeutic Target in Lung and Head and Neck Cancer. 12(3). 6 indexed citations

18.

Ettinger, David S., Mark Agulnik, Justin Cates, et al.. (2011). Occult Primary. Journal of the National Comprehensive Cancer Network. 9(12). 1358–1395. 35 indexed citations

19.

Vidal, Laura, Ming‐Sound Tsao, Gregory R. Pond, et al.. (2009). Fluorescence in situ hybridization gene amplification analysis of EGFR and HER2 in patients with malignant salivary gland tumors treated with lapatinib. Head & Neck. 31(8). 1006–1012. 36 indexed citations

20.

Agulnik, Mark, et al.. (2008). Salivary Gland Malignancies: The Role for Chemotherapy and Molecular Targeted Agents. Seminars in Oncology. 35(3). 309–319. 41 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact